A process for the preparation of a composite comprising a carrier particle and a plurality of drug nanoparticles. The process comprises providing a suspension of drug nanoparticles in the presence of a carrier particle, the carrier particle having an external surface that is functionalised with a surface treatment agent. The process simplifies isolation of drug nanoparticles from suspension.

Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (off) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (on) the bioactive peptide or binding domain, components of such protein switches, and their use.

A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 m or less, and which may be homogeneous.

Described herein are polyhedral, three-dimensional tunable nanocages assembled with a multimeric protein covalently linked to a polynucleotide handle and a DNA origami base assembly including sequences complementary to the polynucleotide handles, wherein the polynucleotide handle and the complementary sequences hybridize to for double-stranded DNA helices.

Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (off) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (on) the bioactive peptide or binding domain, components of such protein switches, and their use.

Composites comprising a metal carbonate and organic agent included within a crystal lattice of the metal carbonate are disclosed. Process of preparing the composites is also disclosed. Uses of the composites, in medicine, are also disclosed.

The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.

Methods of purification for the large scale synthesis of CB[7]-PEG may include at least one of diafiltration or tangential flow filtration, column chromatography, affinity pull-down techniques, or selective precipitation methods. In one embodiment, the method includes providing a reaction mixture containing synthesized CB[7]-PEG, providing a membrane selected to be below the nominal molecular weight of CB[7]-PEG, and removing small molecular weight contaminant species from the reaction mixture using the membrane. In embodiments, regardless of which purification method is used, a copper catalyst component of the click chemistry reaction mixture may be removed using a commercially available metal-chelating resin.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.